identified as an E3 ligase that targets Cdt1 for degradation. Cdt1 is an essential factor for DNA replication licensing that works together with ORC and Cdc6 to load MCM2-7 helicase on replication origins (Maiorano, Moreau, & Mechali, 2000; Nishitani, Lygerou, Nishimoto, & Nurse, 2000; Riera et al., 2017) . Once DNA replication is initiated, Cdt1 is inactivated by CRL4
Cdt2 to inhibit relicensing of replicated DNA (Abbas & Dutta, 2011; Arias & Walter, 2007) . In addition to Cdt1, H4K20 monomethylase Set8, CDK inhibitor p21, Cdc6, and thymine DNA glycosylase (TDG) are substrates of CRL4 Cdt2 (Abbas & Dutta, 2011; Clijsters & Wolthuis, 2014; Nakamura et al., 2017; Slenn et al., 2014) . All these substrate proteins are directly or indirectly involved in replication licensing or genome integrity. CRL4 Cdt2 is unique in that this E3 ligase requires PCNA that is loaded onto chromatin (Arias & Walter, 2006; . When DNA replication starts, PCNA is loaded onto chromatin and acts as a platform for various proteins involved in DNA replication and chromatin metabolism. Most of these proteins associate with PCNA through their PCNAinteracting protein (PIP) box (Choe & Moldovan, 2017; Shiomi & Nishitani, 2017) . In contrast, CRL4 Cdt2 substrates have a specialized PIP-box, the so-called PIP-degron-a canonical PIP-box and TD amino acids within the box and basic residue(s) downstream of the box (Havens & Walter, 2009; Michishita et al., 2011) . When the PIP-degron proteins bind to PCNA on DNA, CRL4 Cdt2 recognizes the resulting complexes for poly-ubiquitination. This replication-coupled degradation creates an important feedback mechanism by linking the initiation of DNA replication to shutdown of replication licensing (Abbas & Dutta, 2011; Arias & Walter, 2007) . The same destruction mechanism works when cells are exposed to DNA-damaging irradiation or reagents (Ralph, Boye, & Kearsey, 2006; Stathopoulou et al., 2012) . For example, Cdt1 is degraded within minutes after UV irradiation, depending on chromatin loading of PCNA (Raman, Havens, Walter, & Harper, 2011; Shiomi et al., 2012) . The degradation of CRL4 Cdt2 substrates enhances the accessibility of DNA polymerases to the DNA damaged sites and is important for repair synthesis (Tanaka et al., 2017; Tsanov et al., 2014) . In human cells under normal culture conditions, Cdt2 is present in the nuclei at almost similar levels throughout the cell cycle (Ishii et al., 2010) . CRL4
Cdt2 activity is essentially dependent on the chromatin-bound PCNA. Upon initiation of S phase, PCNA is loaded and Cdt2 target proteins are quickly degraded. At the end of S phase, PCNA is off the chromatin, and substrates such as p21 and Set8 begin to accumulate (Abbas et al., 2010; Nishitani et al., 2008) , whereas Cdt1 is still targeted by CRL1 Skp2 during G2 phase. However, the phosphorylation levels of Cdt2 dramatically fluctuate during the cell cycle. Previous analysis with a synchronized human cell culture showed that whereas Cdt2 is either not phosphorylated or under-phosphorylated during G1 phase, it is phosphorylated upon entering into S phase and its levels further increase as cells enter M phase (Ishii et al., 2010) . Phosphorylated Cdt2 is also observed in G1 phase, when cells are irradiated with UV and Cdt1 is degraded. These observations suggest that Cdt2 phosphorylation is related to substrate degradation. The phosphorylation levels during the cell cycle well reflect CDK activity. In human cells, Cdt2 phosphorylation at T464 by CDK stabilizes Cdt2 by protecting it from CRL1 Fbxo11 ubiquitin ligase, which recognizes Cdt2 around amino acid T464 (Abbas et al., 2013; Dar, Wu, Lee, Shibata, & Dutta, 2014; Rossi et al., 2013) . Including T464, human Cdt2 has 22 CDK phosphorylation consensus S/T-P sites ( Figure 1a ), 18 of which are in the C-terminal region, suggesting that phosphorylation by CDKs has a greater role in Cdt2 than just regulating its stabilization. Findings from a recent study using a Cdk1 inhibitor suggested that Cdk1 blocks CRL4 Cdt2 activity by preventing its recruitment to chromatin from late S phase, even though PCNA is still on the chromatin (Rizzardi et al., 2015) . Such a mechanism may facilitate the re-accumulation of Cdt1, p21, and Set8 toward M phase. Importantly, those proteins have roles and function during M phase. In addition, in contrast to G1 phase, when Cdt2 substrates were degraded after UV irradiation, they were refractory to degradation in M phase, probably due to Cdt2 phosphorylation (Morino et al., 2015; Rizzardi et al., 2015) . It remains unclear, however, whether Cdk1 acts directly or indirectly, or in combination with other CDKs to inhibit CRL4 Cdt2 , and how CDKs regulate CRL4 Cdt2 activity. Cdt2 is composed of two domains; the N-terminal half region containing seven WD40 repeats and the extended Cterminal half region, whose function is not well known. Here, to evaluate the regulation of CRL4 Cdt2 by CDKs in human cells, we mutated Cdt2 at all of the CDK consensus phosphorylation sites in its C-terminal half region (Cdt2-18A). The mutation led to increased affinity of CRL4 Cdt2 to PCNA, and cells expressing Cdt2-18A possessed higher polyubiquitination activity. Our data suggest that CDK-mediated phosphorylation of Cdt2 blocks its activity by preventing its association with PCNA. the C-terminal half region (Figure 1a) . To clarify the phosphorylation-related regulation of Cdt2, especially by CDKs, we first performed an in vitro kinase assay for Cdt2 with cyclin A/Cdk2 and cyclin B/Cdk1, major kinases acting during S phase and M phase, respectively. The CRL4 Cdt2 complex was purified from insect cells and incubated with cyclin A/Cdk2 or cyclin B/Cdk1 (Figure 1b ). Both kinases phosphorylated Cdt2, but other components of CRL4 were hardly phosphorylated, indicating that Cdt2 is a substrate of CDKs. We then mutated Cdt2 at the serine (S) or threonine (T) of the CDK consensus phosphorylation sites (S/T-P) to alanine (A). We focused on the C-terminal region to avoid affecting substrate recognition by mutating the WD40 repeat region. In addition, in the PhosphoSitePlus database (Hornbeck, Chabra, Kornhauser, Skrzypek, & Zhang, 2004) , although the number of records for each phosphorylation site differed, all the sites in the C-terminal region, but only one in the N-terminal region, were identified as positive for phosphorylation. Thus, we mutated all 18 CDK sites in the C-terminal region (designated Cdt2-18A) and expressed F I G U R E 1 Cdt2 was phosphorylated by CDKs and cell cycle-dependent phosphorylation was lost in the Cdt2-17A and -18A mutants.
| RESULTS

| Phosphorylation of Cdt2 by
(a) CDK consensus phosphorylation sites in human wild-type Cdt2 (WT), and mutation sites of Cdt2-17A, and -18A are shown. The black lines indicate the positions of serine or threonine substituted with alanine in the CDK consensus sites. Each type of Cdt2 was expressed as a form with an N-terminal HA tag and C-terminal 3 × FLAG tag. (b) The CRL4 Cdt2 complex was purified from insect cells as described in the Section 4. The complex was incubated in the presence (+) or absence (−) of cyclin A/Cdk2 or cyclin B/Cdk1. After SDS-PAGE, gels were stained with Coomassie Brilliant Blue R-250 (CBB), exposed to X-ray film, and 32 P-incorporated bands were detected ( 32 P 
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with the 3xFLAG tag at the C-terminal end (Figure 1a) . We also created a 17-site mutant that retained the T464 CDK site (Cdt2-17A), the site at which phosphorylation is important for Cdt2 stabilization . In cells expressing Cdt2-17A or Cdt2-18A, phosphorylation was almost completely blocked, which was further confirmed by electrophoresis on Phos-tag gels and by phosphatase treatment (Figure 1c) . Studies of synchronized cells also confirmed that phosphorylation of these proteins was mostly blocked not only in S phase, but also in M phase (Figure 1d , see also Figure 5b for cell cultures synchronized by double-thymidine block and release). As Cdt2-T464A was reported to be refractory to CRL1 Fbxo11 binding and thus stabilized , the T464A mutation abolishes the effect of T464 phosphorylation on Cdt2 stability and Cdt2 remained stable irrespective of the T464 mutation in cells expressing Cdt2-17A or Cdt2-18A. Hence, we used cells stably expressing Cdt2-18A in subsequent experiments to evaluate the role of phosphorylation in CRL4 Cdt2 activity. The expression levels of Cdt2-WT and Cdt2-18A were similar, and the frequency of expressing cells was more than 90% for each stable cell line ( Figure 3a ). An immunoprecipitation assay showed that both DDB1 and Cul4A co-immunoprecipitated with Cdt2-18A at levels similar to Cdt2-WT, confirming that Cdt2-18A formed a CRL4 complex (Figure 2a) . The 18A mutation led to a reduction in the in vitro phosphorylation. For this assay, we isolated the CRL4 Cdt2 complex from HEK293 cells stably expressing Cdt2-WT or Cdt2-18A with anti-FLAG resins. The phosphorylation levels of Cdt2 by cyclin A/Cdk2 in Cdt2-18A were reduced to approximately one-fifth that in Cdt2-WT (Figure 1e left). The activity of commercially obtained cyclin B/Cdk1 was not strong enough for the present assay, and therefore, we used a lysate prepared from insect cells over-expressing F I G U R E 2 Cdt2-18A has higher affinity to PCNA and chromatin than wild-type Cdt2. (a) HEK293 and HEK293 cells stably expressing Cdt2-WT or Cdt2-18A were used without cross-linking (−) for immunoprecipitation with anti-FLAG antibody. The bound proteins were analyzed. (b) Cells were cross-linked with formaldehyde (+) and were used for immunoprecipitation with anti-FLAG beads. The amounts of bound PCNA were normalized with DDB1, expressed relative to the Cdt2-WT sample (n = 3). (c) Cell lysates were prepared from the indicated cells with 100 mM NaCl-containing CSK buffer. Whole cell extract (WCE) was separated into supernatant (Sup) and chromatin-containing precipitate (Ppt) after centrifugation. The precipitates were washed and extracted with the same buffer, but different concentrations of NaCl (100, 200, and 300 mM). Indicated proteins were examined by immunoblotting. The arrowhead and the arrow show hyper-and hypophosphorylated Cdt2, respectively cyclin B and Cdk1 as previously described (Firpo, Koff, Solomon, & Roberts, 1994) . The kinase activity of the lysate to histone H1 was blocked in the presence of its Cdk1 inhibitor, RO-3306 ( Figure S1a ). Using this preparation of cyclin B/Cdk1, we confirmed that Cdt2 phosphorylation in Cdt2-18A protein was also reduced to almost one-fifth (Figure 1e right). These results show that Cdt2 is a target of both cyclin A/Cdk2 and cyclin B/Cdk1, and that the mutated sites in Cdt2-18A included target sites for these kinases.
2.2 | Cdt2-18A has a stronger association with PCNA than Cdt2-WT
Because it was suggested that phosphorylation of Cdt2 negatively regulates its binding to chromatin or PCNA, we examined and compared the chromatin association of Cdt2-WT and Cdt2-18A using a cell fractionation assay after high-salt extraction of the chromatin-containing fraction. The levels of RCC1 retained on the chromatin decreased as the salt concentration increased, but the reduction was rather similar between the three cell lines, HEK293 and HEK293 expressing Cdt2-WT, or Cdt2-18A ( Figure 2c ). PCNA and histone H3 were resistant to extraction in the salt concentrations used here. In contrast, chromatin association differed between Cdt2-WT and Cdt2-18A. Cdt2-18A was retained on chromatin after higher salt extraction compared with Cdt2-WT ( Figure 2c ), indicating that Cdt2-18A more strongly associated with chromatin than Cdt2-WT. In the Cdt2-WT fractionations, hypophosphorylated Cdt2, but not the hyperphosphorylated form, was recovered in the 100-mM salt precipitates, suggesting that hypophosphorylated Cdt2 has a higher affinity to chromatin, although it was easily dissociated when using a higher salt concentration. As CRL4 Cdt2 is recruited to chromatin-loaded PCNA, the above results suggested that Cdt2-18A associated strongly with chromatin through interaction with PCNA. We then examined whether the interaction of Cdt2 with PCNA was increased by CDK site mutation. Without cross-linking treatment before immunoprecipitation, PCNA was hardly detected above control levels in both Cdt2-WT and Cdt2-18A precipitates (Figure 2a ). We therefore treated the cells with a cross-linking reagent and proceeded with the immunoprecipitation. In this condition, PCNA coprecipitated with both Cdt2-WT and Cdt2-18A (Figure 2b) . A higher amount of PCNA, however, was consistently detected in Cdt2-18A precipitates compared with Cdt2-WT precipitates, suggesting that Cdt2-18A had higher affinity for PCNA. In addition, we noticed that cyclin A coprecipitated with Cdt2, and in higher amounts in the Cdt2-WT precipitates compared with Cdt2-18A precipitates. The amounts of coprecipitated DDB1 or Cul4A were similar between Cdt2-WT and Cdt2-18A, irrespective of fixation.
To assess whether in fact Cdt2-18A had higher affinity for PCNA, we costained cells with antibodies against PCNA and FLAG (to detect ectopically expressed Cdt2-WT or Cdt2-18A) and examined FLAG staining at the PCNA foci. Without pre-extraction, all the cell nuclei were stained with PCNA and also stained with FLAG antibodies, except in HEK293 cells. The intensity of the PCNA and FLAG staining did not differ much between cells expressing Cdt2-WT and Cdt2-18A (Figure 3a) . After the cells were extracted and fixed, PCNA was retained on S phase nuclei, and PCNA foci, which represent DNA replication sites, were observed (Figure 3b,c) . There was no difference in the staining pattern or intensity of PCNA between the three cell lines. In control HEK293 cells, the FLAG signal was negative. In contrast, FLAG (Cdt2-WT) was detected in PCNApositive nuclei (Figure 3b,c) . Cdt2-WT staining appeared to be stronger in cells with PCNA foci in early S phase than those in late S phase. In sharp contrast to the staining without pre-extraction, very strong Cdt2-18A staining was observed in PCNA-positive nuclei compared with Cdt2-WT staining. PCNA-negative cells in G1 or G2 phase were not stained with Cdt2-WT or Cdt2-18A. Costained nuclei indicated that both Cdt2-WT and Cdt2-18A colocalized with PCNA (Figure 3b,c) . The Cdt2 staining intensity was well correlated with the PCNA staining intensity; nuclei with stronger PCNA staining had stronger Cdt2 staining in both Cdt2-WT and Cdt2-18A (Figure 3d ). In addition, when nuclei with similar PCNA intensity were compared, Cdt2-18A showed stronger staining than Cdt2-WT. These results indicated that Cdt2 associated with chromatin-bound PCNA and that the affinity of Cdt2-18A for PCNA was higher than that of Cdt2-WT. PCNA staining patterns changed during the progression of S phase. In contrast to Cdt2-WT staining, Cdt2-18A staining showed that almost all PCNA-positive cells were strongly costained with Cdt2-18A (Figure 3b,c) , suggesting that Cdt2-18A associated with PCNA throughout S phase. Taken together, these findings are consistent with the idea that phosphorylations of Cdt2 reduce its affinity for PCNA.
| Cdt2-18A has higher ubiquitination activity
We thought that the increased affinity of Cdt2-18A to PCNA might influence the degradation of target proteins. We compared Cdt1 protein levels between cells stably expressing Cdt2-18A and Cdt2-WT after treatment with cycloheximide (CHX). After adding CHX, Cdt1 levels were reduced in HEK293 cells, and the degradation kinetics were enhanced in Cdt2-WT-expressing cells ( Figure S2a ). Cdt1 degradation was also accelerated in Cdt2-18A-expressing cells, but at a similar level to that in Cdt2-WT (see Section 3). We then compared the poly-ubiquitination activity of Cdt2-WT and Genes to Cells
Cdt2-18A for Cdt1 after MG132 treatment. In this assay, the poly-ubiquitination of Cdt1 was more clearly observed in Cdt2-18A-expressing cells than in Cdt2-WT-expressing cells ( Figure S2b ). After treatment with MG132 for 30 min, poly-ubiquitinated Cdt1 was clearly detected and further increased upon longer incubation of these cells. To further verify that Cdt2-18A has higher poly-ubiquitination activity than Cdt2-WT, we depleted the endogenous Cdt2 with siRNA targeted for the 3′ UTR of Cdt2 and assayed for Cdt1 poly-ubiquitination. The endogenous Cdt2 was efficiently depleted, and the Cdt2-18A stable cells expressed an enhanced poly-ubiquitination of Cdt1 compared with Cdt2-WT (Figure 4) . These results suggested that increased affinity of Cdt2-18A to PCNA led to higher ubiquitination activity to Cdt1.
| Accumulation of substrates during
G2-M phases was abrogated in Cdt2-18A-expressing cells
Because Cdt2-18A associated with PCNA throughout S phase and had higher ubiquitination activity, we thought that accumulation of CRL4 Cdt2 target proteins in the cell cycle might be compromised. HEK293, and Cdt2-WT or Cdt2-18A cells were arrested at early S phase by a double-thymidine block and released synchronously into S phase. Flow cytometry analysis showed that all three cell lines progressed through the cell cycle with a similar time schedule: completion of S phase at ~6 hr and entry into G1 phase by 12 hr (Figure 5a ). Consistently, cell cycle marker proteins, such as cyclin A, cyclin B1, and phospho-histone H3 Ser10 (H3 pS10), exhibited 
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a similar pattern over the time course (Figure 5b ). Cyclin B1 levels peaked at 6 hr, and levels of the M phase marker, H3 pS10, were highest at 9 hr. The Cdt2 proteins, both endogenous and Cdt2-WT, were phosphorylated during S phase, then hyperphosphorylated in M phase, and de-phosphorylated in G1 phase. In contrast, phosphorylation of Cdt2-18A remained at very low levels throughout the time course. Cdt1 is targeted by both CRL4 Cdt2 and CRL1 Skp2 during S phase, and CRL1 Skp2 still targets Cdt1 during G2 phase (Nishitani et al., 2006) . In addition, SCF(CRL1) Fbxo31 also targets Cdt1 in G2
phase (Johansson et al., 2014) . Therefore, Cdt1 begins to accumulate as cells enter into M phase (6-9 hr) in HEK293 cells and stable Cdt2-WT-expressing cells. Consistent with the fact that Cdt2-18A associated with PCNA throughout S phase and had higher ubiquitination activity, Cdt1 levels in stable Cdt2-18A-expressing cells were lower during S phase, and the accumulation around G2/M phase was slightly reduced as compared with that in Cdt2-WT-expressing cells (Figure 5b ,c). However, Set8 targeted only by CRL4 Cdt2 in S phase and therefore begins accumulating around late S phase-G2 phase, earlier than Cdt1 (Abbas et al., 2010; Rizzardi et al., 2015) . The Set8 levels peaked when cells were in mitosis, as reported previously (Wu et al., 2010) and then reduced as cells progressed through M phase into G1 phase in HEK293 cells (Figure 5b ). In Cdt2-WT cells, the accumulation of Set8 around late S-G2 phases was slightly reduced. In Cdt2-18A cells, Set8 levels during S phase were much lower and the accumulation of Set8 in the late S-G2 phases to M phase was compromised, suggesting that the tight interaction between Cdt2-18A and PCNA prevented Set8 accumulation. Similar results were obtained for another substrate, TDG. In the case of Cdt1, it is still targeted by both CRL1 Skp2 and SCF(CRL1) Fbxo31 , and PCNA comes off chromatin during G2 phase. Therefore, there was only slight effect of Cdt2-18A on Cdt1 accumulation around M phase and G1 phase. Anyway, consistent with the fact that Cdt2-18A strongly associated with PCNA throughout S phase, the substrate levels were lower in these stable cells from early S phase.
| Cdt2-18A induced the degradation of Cdt2 substrates in M phase after UV irradiation
Previous studies showed that CRL4 Cdt2 substrates including Cdt1 were not degraded after UV irradiation in mitosis, although PCNA was loaded onto chromatin (Morino et al., 2015; Rizzardi et al., 2015) . If this were due to the inhibitory phosphorylation of Cdt2, Cdt2-18A would overcome the inhibition and induce Cdt1 degradation after UV irradiation in mitosis. In asynchronously growing cultures of HEK293 cells and cells expressing Cdt2-WT or Cdt2-18A, Cdt1 was degraded after UV irradiation. Next, we synchronized cells in mitosis with nocodazole and evaluated Cdt1 degradation.
In all cell lines, Cdt1 was detected at almost similar levels in M phase in phosphorylated forms. When cells were irradiated with UV, Cdt1 was not degraded in HEK293 cells, as reported ( Figure 6 ). This was also the case for the Cdt2-WTexpressing cells. In contrast, Cdt1 was degraded in Cdt2-18A-expressing cells. Similar results were obtained for Set8, although the Set8 levels were low in Cdt2-18A cells in mitosis, as mentioned above. Together, these findings imply that Cdt2 phosphorylation plays an important role in regulating CRL4
Cdt2 activity during the cell cycle.
| DISCUSSION
CRL4
Cdt2 -mediated proteolysis during the cell cycle is controlled primarily by PCNA loading onto the chromatin. In addition, phosphorylation-related regulation of CRL4 Cdt2 activity has been suggested (Rizzardi et al., 2015) . In the Relative Cdt1 levels present study, we showed that Cdt2 was phosphorylated by both S phase-and M phase-specific CDKs, cyclin A/ Cdk1 and cyclin B/Cdk2, respectively, in vitro. To evaluate the role of Cdt2 phosphorylation by CDK, we mutated all CDK consensus phosphorylation sites in the C-terminal region of Cdt2. The 18A mutation led to the reduction in phosphorylation both in vitro and in vivo. The mutant Cdt2, Cdt2-18A, had higher affinity for PCNA throughout S phase. Consistently, poly-ubiquitination of Cdt1 was enhanced in cells expressing Cdt2-18A. Other targets, Set8 and TDG, were maintained at low levels throughout S phase and their accumulation around the late S/G2 phases was inhibited. Furthermore, we found that Cdt1 was degraded in mitosis after UV irradiation in Cdt2-18A-expressing cells. Based on the analysis at PhosphoPlus sites (Hornbeck et al., 2004) , phosphorylation is expected at all of the sites mutated in the present work. Together, our findings suggest that CDKdependent multiple-phosphorylation negatively regulates Cdt2 activity by rendering Cdt2 inhibitory to PCNA binding, indicating that phosphorylation of Cdt2 by CDK creates another layer of regulation on CRL4 Cdt2 activity. At present, however, we do not know whether all 18 predicted CDK phosphorylation sites are involved or whether there are critical sites among them for such a regulatory role. We also cannot exclude the possibility that the alanine mutation at the 18 sites induced a structural change in Cdt2 leading to increased affinity to PCNA. It is also possible that other S/T-P directed kinases are involved. As for such kinases, our previous report (Sakaguchi et al., 2012) suggested that Cdt2 phosphorylation was not affected by the inhibitors for MAP kinases (ERK, JNK, and p38). How is Cdt2 phosphorylation connected to CRL4 Cdt2 activity to regulate the cell cycle-dependent substrate degradation and accumulation? Cdt2 phosphorylation levels fluctuate during the cell cycle, that is, low during G1 phase, high during S phase, and further increased toward M phase (Ishii et al., 2010; Figure 5b) . PCNA loading at the beginning of S phase induces rapid degradation of the initiator protein Cdt1 by recruiting CRL4
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. Other CRL4 Cdt2 target proteins, Set8 and p21, must also be degraded to prevent re-replication or to activate CDKs. If Cdt2 phosphorylation negatively regulates Cdt2 activity from the beginning of S phase, the degradation of such proteins at the initiation of S phase would be delayed, leading to illegitimate events. Because Cdt2 phosphorylation is low in G1 phase, it is probable that Cdt2 is not fully phosphorylated at the beginning of S phase. In this regard, an interesting finding is that p21 degradation was delayed compared with that of Cdt1 and Set8, which keeps Cdk2 activity at an intermediate level during early S phase . We observed that there was no difference in the Cdt1 degradation between Cdt2-WT or Cdt2-18A expressing cells after cycloheximide treatment ( Figure S2a ). This assay mostly reflects the degradation of Cdt1 in cells just entered into S phase. As mentioned above, at an early stage of S phase, phosphorylation levels of Cdt2-WT are low, and thus, Cdt2-WT could have a similar ubiquitination activity to Cdt2-18A. However, as cells complete DNA replication, they prepare to initiate mitosis. Importantly, Cdt1, Set8, and p21 are all required for proper M phase progression (Dulic, Stein, Far, & Reed, 1998; Houston et al., 2008; Kreis, Sanhaji, Rieger, Louwen, & Yuan, 2014; Varma et al., 2012) . A previous report showed that Set8 and p21 begin to accumulate around late S phase, even though PCNA was still on chromatin (Rizzardi et al., 2015) . Cdt1 accumulation was delayed because CRL1 Skp2 continues to act on Cdt1 during these periods (Nishitani et al., 2006) . From late S phase to M phase, Cdt2 is further phosphorylated (Ishii et al., 2010) , which could prevent CRL4 Cdt2 from binding to PCNA, and thus enhance the accumulation of Set8 and p21. In early S phase-arrested cells by a double-thymidine block, Cdt2 was already detected as a phosphorylated form (Figure 5b ), probably due to the arrest in early S phase by inhibition of DNA replication. In a synchronized culture further progressed into the cell cycle, ~18-20 hr, cells re-entered a second S phase (Ishii et al., 2010) . Around these time-points, when Cdt1 degradation started, Cdt2 phosphorylation levels also began to increase. Based on these observations, we surmise that CRL4 Cdt2 during early S phase is in a lower phosphorylated state due to low levels of cyclin A and thus is able to associate with PCNA for rapid substrate degradation. As S phase progresses, cyclin A levels increase and as cells complete DNA replication, cyclin B also accumulates, leading to an increase in their associated CDK activities and thus further Cdt2 phosphorylation. The higher phosphorylated form of Cdt2 becomes refractory to PCNA binding. In accordance with such a prediction, the hypophosphorylated Cdt2-WT had a higher affinity to chromatin (Figure 2c ), and costaining of Cdt2-WT with PCNA foci was more strongly observed in early S phase cells (Figure 3b,c) . In addition, when Cdt2-WT was incubated together with cyclin A/Cdk2 and cyclin B/Cdk1 in an in vitro kinase assay, the phosphorylation levels increased, though slightly, as compared with the cases assayed with either cyclin A/Cdk2 or cyclin B/Cdk1 alone, suggesting that cyclin B/Cdk1 additionally phosphorylated other sites than those phosphorylated by cyclin A/Cdk2 ( Figure S1b ). Phosphorylation of Cdt2 during S phase may contribute to another aspect of chromosomal events. Because many proteins associate with PCNA and function during DNA replication, phosphorylation-mediated inhibition of CRL4 Cdt2 binding to PCNA may prevent stable binding from interfering with the function of proteins working on PCNA. In addition, some of the Cdt2 phosphorylation might increase its activity, as in the case of UV irradiation, where ATR (ataxiatelangiectasia mutated and Rad3 related) -mediated Cdt2 phosphorylation appears to positively regulate Cdt1 degradation (Sakaguchi et al., 2012) .
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How does phosphorylation of Cdt2 inhibit CRL4
Cdt2 association with PCNA? Xenopus Cdt2 binds directly to PCNA through its C-terminal domain (Kim et al., 2010) . Although human Cdt2 and Xenopus Cdt2 have low similarity in the C-terminal region (39%; the N-terminal region has higher similarity, 73%), among the 18 CDK consensus sites of human Cdt2, 13 sites are conserved between the two species. Thus, such PCNA-interacting activity can also be conserved in human Cdt2. We think that multiple phosphorylations of Cdt2 lead to structural changes that reduce its binding affinity to PCNA. Phosphorylation also creates a site for protein interaction, which could inhibit PCNA binding. Phosphorylation of T464 leads to 14-3-3 binding, although its binding to pT464 is reduced in M phase as compared in S phase . Another possibility is that multiple phosphorylations make Cdt2 refractory to binding to chromatin or DNA itself due to an increase in its negative charge. The multiple CDK sites in Cdt2 are clustered in the first one-third and last onethird of the C-terminal region. Clustered phosphorylation sites are sometimes found in disordered proteins. In fact, PONDER analysis (Predictor Of Naturally Disordered Regions, <http://www.pondr.com>) suggests that most of the C-terminal region of Cdt2 is disordered. Multiple phosphorylations can generate a signaling system where the system is triggered when phosphorylation levels reach a threshold (Valk et al., 2014; Wright & Dyson, 2015) . Such a mechanism can be applied to CRL4
Cdt2 regulation as follows. At low or intermediate CDK activity in early S phase to middle S phase, CRL4 Cdt2 is in a low phosphorylation state and is thus able to associate with PCNA and actively function as a ubiquitin ligase. As cells are completing DNA replication, CDK activity increases. Accordingly, Cdt2 phosphorylation levels reach a threshold, which could result in a structural change that abolishes its binding activity to PCNA. Such a mechanism could generate a fine strategy for regulating cell cycle-dependent protein degradation and accumulation. In this sense, those sites that are phosphorylated around late S-G2 phases to M phase may have a critical role in the regulation of Cdt2. Further studies are needed to identify PCNA-interacting domains in Cdt2 and to clarify how phosphorylations of Cdt2 by CDK reduce the affinity of Cdt2 to PCNA.
| EXPERIMENTAL PROCEDURES
| Cell culture
HEK293 and HEK293 cells stably expressing Cdt2-WT, Cdt2-17A, or Cdt2-18A were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 5% CO 2 . For transient transfection into HEK293 cells, polyethyleneimine was used. To isolate stably expressing HEK293 cell lines, cells were transfected with pCMV-HACdt2(WT)-3 × FLAG, pCMV-HA-Cdt2(17A)-3 × FLAG, or pCMV-HA-Cdt2(18A)-3 × FLAG using polyethyleneimine, and selected in a medium containing 400 μg/ml G418. HEK293 cell lines were synchronized in early S phase by a double-thymidine block (2 mM thymidine for 18 hr, release for 8 hr, and then 2 mM thymidine for 18 hr). To synchronize in M phase, cells were plated and cultured for 24 hr, incubated in the presence of 2 mM thymidine for 20 hr, washed with phosphate-buffered saline (PBS) twice and once with medium, and cultured in the presence of 400 ng/ ml nocodazole for 14 hr. Proteasome inhibitor MG132 was used at 25 μM. Cycloheximide was used at 100 μg/ml. UV-C (254 nm) irradiation of whole cells in dishes was performed in the presence of 0.5 ml Dulbecco's modified Eagle's medium in 35-mm dishes at 50 J/m 2 using a UV cross-linker (FS-800, Funakoshi). For analysis of DNA content by flow cytometry, synchronized HEK293 cell lines were fixed in 70% ethanol, treated with RNase A (100 μg/ml) for 1 hr, and stained with propidium iodide (12.5 μg/ml), and measured on FACScan (BD Biosciences).
| Plasmids
The wild-type Cdt2 expression plasmid, pCMV-HACdt2(WT)-3 × FLAG, was described previously (Sakaguchi et al., 2012) . To construct the 18 CDK phosphorylation site mutant of Cdt2(18A), the C-terminal half DNA of Cdt2 (aa 363-730) harboring the 18 S/T-A substitutions was synthesized by Eurofins Genomics, cut with NdeI and NotI, and cloned into the pCMV-HA-Cdt2(WT)-3 × FLAG by fragment swapping to generate pCMV-HACdt2(18A)-3 × FLAG. The resulting plasmid was verified by sequencing. To construct pCMV-HA-Cdt2(17A)-3 × FLAG, A464 of pCMV-HA-Cdt2(18A)-3 × FLAG was restored to threonine by site-directed mutagenesis using primer-17A-fw, CTTCCTTCAAATACTCCTACG, and primer-17A-rv, GAACGTAGGAGTATTTGAAGG.
| Antibodies, Western blotting, and immunofluorescence
For Western blotting, whole cell lysates were prepared by lysing cell pellets directly in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) buffer. To separate phosphorylated proteins on SDS-PAGE, Phos-tag (10 μM; the NARD Institute; AAL-107) was used according to the manufacturer's instructions. For λ-phosphatase treatment, cell extracts were prepared using 0.1% Triton X-100-containing CSK buffer (10 mM Pipes, pH7.9, 100 mM NaCl, 300 mM sucrose, 1 mM phenylmethylsulfonyl fluoride, and 1 × protease inhibitor cocktail; Roche Applied Science); λ-phosphatase (New England BioLabs) was added, and the extracts were incubated at 30°C for 30 min. The reaction was subsequently stopped with SDS-PAGE buffer. For immunofluorescence, cells were fixed in 4% paraformaldehyde (WAKO) for 10 min, washed with phosphate-buffered saline (PBS), fixed again in ice-cold methanol for 1 min, and stained with the indicated antibodies. To visualize chromatin-bound proteins, cells were pre-extracted with PBS containing 0.5% Triton X-100, fixed in 4% paraformaldehyde solution, washed with PBS, and fixed again in ice-cold methanol for 10 min (Morino, Tanaka, Shiomi, & Nishitani, 2014) . As secondary antibodies, Alexa Fluor 488-conjugated anti-mouse antibody and Alexa Fluor 594-conjugated anti-rabbit antibody were used with Hoechst 33258 to visualize the DNA. The following primary antibodies were used: Cdt2 (laboratory stock, (Nishitani et al., 2008) ); Cdt1 (laboratory stock, (Nishitani, Taraviras, Lygerou, & Nishimoto, 2001) ); Set8 (06-1304, Millipore); TDG ( (Nakamura et al., 2017) ) RCC1 (laboratory stock, (Shiomi et al., 2012) 
| RNA-interference knockdown experiments
Double-stranded RNAs were transfected at 100 nM using Lipofectamine 2000 and culture for 48 hr. The following siRNAs were made by Dharmacon: Cdt2; GCUGAGCUUUGGUCCACUA dTdT, and siRNA for luciferase (siLuc), known as GL2, used as a control siRNA.
| Chromatin fractionation
Cell extracts were prepared using 0.1% Triton X-100-containing CSK buffer (10 mM Pipes, pH7.9, 100 mM NaCl, 300 mM sucrose, 1 mM phenylmethylsulfonyl fluoride, and 1 × protease inhibitor cocktail; Roche Applied Science). Cells were washed with ice-cold PBS and lysed with 0.1% Triton X-100-containing CSK buffer for 10 min. After centrifugation (300 g, 5 min at 4°C), the precipitate was washed and extracted with the same volume of ice-cold 0.1% Triton X-100-containing CSK buffer with 100, 200, or 300 mM NaCl, and precipitates were subsequently suspended in SDS sample buffer.
| Cross-linking and immunoprecipitation
Cells were harvested by centrifugation at 3,000 rpm (900 g) for 3 min, washed twice with PBS, and fixed in 1 ml PBS containing 0.1% paraformaldehyde for 10 min at room temperature. After washing twice with 1 ml PBS, the cells were lysed with 400 μl 0.1% Triton X-100 containing CSK buffer (10 mM Pipes, pH 7.9, 100 mM NaCl, 300 mM sucrose, 0.1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 mM ß-glycerophosphate, 1 mM Na 3 VO 4 , 10 mM NaF, and 1 × protease inhibitor cocktail [Roche Applied Science]) on ice. Cell lysates were sonicated (output 3, duty cycle 20%, three sets of five beats and 1-min interval) on ice. Cell lysates were adjusted to 400 μl and 2 mg/ml protein and clarified by centrifugation at 13,500 rpm (17,700 g) for 15 min at 4°C. The supernatants (320 μl) were mixed with 10 μl bed volume of anti-FLAG M2 Affinity gel (Sigma-Aldrich) beads and rotated for 90 min at 4°C. The affinity gel beads were washed three times with 200 μl CSK buffer, mixed with 1 × SDS sample buffer, and boiled to make the bound fraction sample.
| Purification of the CRL4
Cdt2 complex
Baculoviruses for Cdt2-3 × FLAG, DDB1, HA-Cul4, and His-myc-Rbx1 were co-infected into Sf21 cells and purified as described (Hayashi, Suenaga, Shiomi, & Nishitani, 2014) . Briefly, the cell lysate was prepared with 0.5 M NaCl and 0.5% NonidetP-40 containing Buffer B (50 mM Tris-HCl pH 8.0, 10% glycerol, 1×protease inhibitor cocktail EDTA-free (Roche Applied Science), 1 mM PMSF, and 2 μg/ml leupeptin) and clarified by centrifugation. The supernatant was mixed with anti-FLAG M2 Affinity gel (Sigma-Aldrich) beads. Beads were washed and treated with λ-protein phosphatase (1 unit/μl) as described by the supplier (New England BioLabs) at 30°C for 60 min. After washing the beads with Buffer B containing 0.1 M NaCl, 0.1% NP-40, CRL4 Cdt2-3×FLAG was eluted with Buffer B containing 0.1 M NaCl, 0.1% NP-40, and 200 μg/ml 3 × FLAG peptide (Sigma-Aldrich).
To immunopurify CRL4 Cdt2 complexes, HEK293 stable cells expressing either 3 × FLAG-tagged Cdt2-WT or Cdt2-18A were lysed in a kinase buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, and 100 mM NaCl) supplemented with 0.1% Triton X-100, 1×protease inhibitor cocktail EDTA-free (Roche Applied Science) and 1 mM PMSF, and clarified by centrifugation at 13,500 rpm (17,700 g) for 15 min at 4°C. The 5 mg of supernatants was mixed with 10 μl of anti-FLAG M2 beads and rotated for 90 min at 4°C. The affinity gel beads were washed three times with 500 mM NaCl-containing kinase buffer and then normal kinase buffer.
Genes to Cells
| In vitro kinase assay
Cyclin A2/Cdk2 (SignalChem) and cyclin B1/Cdk1 (SignalChem, and a kind gift from Dr Jim Roberts, prepared from insect cells over-expressing cyclin B and Cdk1 (cyclin B/Cdk1*) as described previously (Firpo et al., 1994) ) were used in the kinase assay. One hundred nanograms of purified CRL4 Cdt2 complex from Sf21 cells was phosphorylated by the kinase in a reaction mixture containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, 100 mM NaCl, 100 μM ATP, and 5 μCi of [γ-32 P]-ATP (NEG502A, 111 TBq/mmol (3,000 Ci/mmol), PerkinElmer, Inc) for 30 min at 30°C. The immunopurified CRL4
Cdt2 complex prepared from HEK293 stable cells expressing either 3 × FLAGtagged Cdt2-WT or Cdt2-18A was assayed in a similar way. The reaction was stopped by adding SDS sample buffer and boiling. After SDS-PAGE, the gel was stained with Coomassie Brilliant Blue (CBB) R-250, dried, and exposed to X-ray film.
